Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dabigatran

dabigatran

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dabigatran

20 trials tracked of dabigatran: 1 in phase 3 or 4.

20Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1 Phase 1 6 Other / NA 12
  1. Phase 3 Secondary Prevention of Venous Thrombo Embolism (VTE). Completed
  2. Phase 2 Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Completed
  3. Phase 1 PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Completed
  4. Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects Completed
  5. Phase 1 A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects Completed
  6. Phase 1 A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants Completed
Show 14 more trials
  1. Phase 1 Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers Completed
  2. Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate Completed
  3. N/A ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years Completed
  4. N/A Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea Completed
  5. N/A Medical Need of OAC Reversal Completed
  6. N/A Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea Completed
  7. N/A A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France Completed
  8. N/A Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Completed
  9. N/A Comparative Effectiveness and Safety Between Warfarin and Dabigatran Completed
  10. N/A Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan Completed
  11. N/A This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke Completed
  12. N/A Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy Completed
  13. N/A Canadian Pradaxa Acute Stroke Safety Study Completed
  14. N/A Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk
Cardiology Meta-analysis
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk Dabigatran may be safest for brain bleeding risk
This network meta-analysis of 127,267 patients with venous thromboembolism or atrial fibrillation found that all DOACs had lower risk of int…
All blood thinners beat warfarin for brain bleed risk, but dabigatran may be the safest choice.
Frontiers May 19, 2026
Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation
Cardiology Meta-analysis
Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation Reversing blood thinners may allow stroke treatment with good safety and recovery
This meta-analysis and case report review examines idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with peripro…
Reversing dabigatran before stroke treatment appears safe, showing low bleeding and death rates with recovery similar to standard care.
Frontiers Apr 22, 2026
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Cardiology Meta-analysis
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Frontiers Apr 15, 2026